Vor Biopharma
VOR
18.20
-0.58
-3.09%
Vor Biopharma
US · VOR
#3175 by market cap
Listed 2021
18.20
-0.58
-3.09%
Live - 5344 symbols - heartbeat 517s ago
· 2026-10-08 09:59
Pre-market
18.64
-0.75%
After-hours
18.78
0.00%
Overnight
18.80
+0.11%
- Market cap
- 1.08B
- P/E (TTM)i
- 1.58
- P/Bi
- -5.38
- EPSi
- -70.50
- Div yieldi
- 0.00%
- 52W posi
- 43%
Reader sentiment
Are you bullish or bearish on VOR?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 427.00K | 4.22M | 11.75M | 21.49M | 28.87M | 31.72M | 27.88M | 50.11M |
| Research & development | 2.43M | 6.20M | 31.62M | 47.53M | 64.55M | 94.32M | 93.31M | 321.53M |
| Operating profit | -2.86M | -10.42M | -43.37M | -69.02M | -93.42M | -126.04M | -121.19M | -371.64M |
| Pretax profit | -4.15M | -10.84M | -43.34M | -68.90M | -92.09M | -117.86M | -116.91M | -695.98M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -4.15M | -10.84M | -43.34M | -68.90M | -92.09M | -117.86M | -116.91M | -695.98M |
| Basic EPS | -15 | -21 | -28 | -42 | -47 | -35 | -34 | -71 |
| Diluted EPS | -14.67 | -20.66 | -28.44 | -42.00 | -46.60 | -35.00 | -34.03 | -70.50 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.59M | 12.79M | 13.97M | 16.77M | 17.57M | 21.93M |
| Research & development | 26.70M | 261.50M | 14.14M | 19.19M | 17.60M | 25.92M |
| Operating profit | -33.29M | -274.28M | -28.11M | -35.96M | -35.16M | -47.85M |
| Pretax profit | -32.49M | -1.57B | -812.68M | 1.72B | -219.59M | -62.81M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -32.49M | -1.57B | -812.68M | 1.72B | -219.59M | -62.81M |
| Basic EPS | -5 | -251 | -122 | 44 | -5 | -1 |
| Diluted EPS | -5.21 | -251.24 | -121.63 | 44.50 | -5.11 | -1.16 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 936.00K | 7.54M | 49.11M | 214.40M | 236.95M | 140.80M | 96.51M | 458.11M |
| Cash & ST investments | 929.00K | 6.47M | 48.54M | 207.47M | 230.25M | 137.18M | 91.93M | 455.21M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.01M | 9.83M | 75.91M | 242.59M | 299.37M | 198.13M | 142.89M | 464.13M |
| Total current liabilities | 7.77M | 2.19M | 10.21M | 10.15M | 13.12M | 15.57M | 18.61M | 25.17M |
| Short-term debt | 4.46M | -- | 863.00K | 1.84M | 3.27M | 3.83M | 4.22M | 280.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 7,774,000.00 | 2,186,000.00 | 27,637,000.00 | 26,327,000.00 | 48,759,000.00 | 47,402,000.00 | 46,227,000.00 | 628,438,000.00 |
| Total equity | -6.77M | 7.64M | 48.27M | 216.26M | 250.61M | 150.72M | 96.66M | -164.31M |
| Retained earnings | -7.05M | -17.89M | -61.22M | -130.12M | -222.22M | -340.08M | -456.99M | -1.15B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 64.85M | 204.93M | 172.49M | 458.11M | 500.78M | 475.11M |
| Cash & ST investments | 60.04M | 200.57M | 170.46M | 455.21M | 491.53M | 466.13M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 109.31M | 205.37M | 176.24M | 464.13M | 506.75M | 481.05M |
| Total current liabilities | 16.73M | 58.77M | 18.84M | 25.17M | 16.08M | 24.81M |
| Short-term debt | 4.27M | -- | 252.00K | 280.00K | 307.00K | 335.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 43,243,000.00 | 1,711,071,000.00 | 2,401,724,000.00 | 628,438,000.00 | 657,170,000.00 | 681,250,000.00 |
| Total equity | 66.07M | -1.51B | -2.23B | -164.31M | -150.42M | -200.20M |
| Retained earnings | -489.48M | -2.06B | -2.88B | -1.15B | -1.37B | -1.44B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.66M | -9.86M | -36.29M | -69.14M | -85.14M | -100.29M | -99.66M | -142.71M |
| Depreciation & amortization | 20.00K | 91.00K | 605.00K | 1.43M | 2.53M | 3.49M | 3.53M | 2.89M |
| Free cash flow | -2.66M | -10.60M | -40.45M | -73.04M | -93.61M | -101.36M | -99.89M | -143.65M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 189.20M | 115.98M | 4.58M | 55.83M | 328.21M |
| Ending cash balance | 929.00K | 8.03M | 50.10M | 122.21M | 60.12M | 33.77M | 84.36M | 396.65M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -31.07M | -35.18M | -53.66M | -22.80M | -38.25M | -25.38M |
| Depreciation & amortization | 825.00K | 2.04M | 2.00K | 23.00K | 28.00K | 36.00K |
| Free cash flow | -31.30M | -35.34M | -53.91M | -23.12M | -38.29M | -25.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 20.26M | 307.95M | 75.00M | 0 |
| Ending cash balance | 52.46M | 192.99M | 160.63M | 396.65M | 170.04M | 108.02M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -89.22 | -39.45 | -58.74 | -94.52 | -- |
| ROA %i | -412.31 | -200.11 | -114.92 | -44.04 | -33.99 | -47.38 | -68.57 | -229.31 |
| ROIC %i | -- | -- | -- | -72.60 | -35.67 | -52.97 | -76.97 | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.12 | 3.45 | 4.81 | 21.12 | 18.06 | 9.04 | 5.19 | 18.20 |
| Quick ratioi | 0.12 | 2.96 | 4.76 | 20.43 | 17.55 | 8.81 | 4.94 | 18.08 |
| Debt / assetsi | 442.80 | 0.00 | 24.10 | 7.43 | 13.00 | 18.00 | 22.28 | 0.65 |
| LT debt / equityi | -- | -- | -- | 7.48 | 14.22 | 21.12 | 28.57 | -- |
| Interest coveragei | -3.14 | -16.83 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -125.43 | -- | -- | -- | -- | -- |
| ROA %i | -85.83 | -959.44 | -1,676.47 | -229.31 | -286.69 | 182.91 |
| ROIC %i | -95.95 | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.88 | 3.49 | 9.16 | 18.20 | 31.15 | 19.15 |
| Quick ratioi | 3.59 | 3.41 | 9.05 | 18.08 | 30.57 | 18.78 |
| Debt / assetsi | 28.16 | 0.00 | 1.74 | 0.65 | 0.58 | 0.60 |
| LT debt / equityi | 40.13 | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 09:59:21 · For reference only, not investment advice and not tailored to your situation.